Safety and Efficacy of 6-thioguanine as a Second-line Treatment for Autoimmune Hepatitis

Clémence Legué (1) , Ludivine Legros (1) , Solène Kammerer-Jacquet (1, 2) , Caroline Jézequel (1) , Pauline Houssel-Debry (1) , Thomas Uguen (1) , Caroline Le Lan (1) , Anne Guillygomarc'H (1) , Romain Moirand (1, 2) , Bruno Turlin (1) , Dominique Guyader (1, 2) , Edouard Bardou-Jacquet (3, 1, 2)

1 Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Ponchaillou]
2 UR - Université de Rennes
3 CIC - Centre d'Investigation Clinique [Rennes]

Corticosteroids and azathioprine provide complete response with good tolerance in most patients for the treatment of autoimmune hepatitis (AIH). Although some patients require second-line treatments, scarce data and side effects hamper consensus on them. Inflammatory bowel diseases (IBD) yielded increasing consideration for azathioprine metabolism and the use of 6-Mercaptopurine (6-MP) or 6-Thioguanine (6-TG), which both exhibit a more direct metabolism to the active metabolite of azathioprine: 6-thioguanine nucleotides (6-TGN).3 Data regarding thiopurines substitution as a second-line therapy for AIH are limited and even more so regarding 6-TG. We herein report our experience with 6-TG after azathioprine failure or intolerance.

Domaines: Pharmacologie; Hépatologie et Gastroentérologie

Clémence Legué, Ludivine Legros, Solène Kammerer-Jacquet, Caroline Jézequel, Pauline Houssel-Debry, et al.. Safety and Efficacy of 6-thioguanine as a Second-line Treatment for Autoimmune Hepatitis. Clinical Gastroenterology and Hepatology, 2018, 16 (2), pp.290-291. ⟨10.1016/j.cgh.2017.07.032⟩. ⟨hal-01717742⟩